A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Gail Geller, ScD, MHS and Paul A. Watkins, MD, PhD
Six cohorts of first-year medical students have been shown to have negative attitudes about obesity that are consistent over time. Attitudes can be improved, however, by using popular media and an ethics framework to discuss personal experiences and beliefs about obesity.
AMA J Ethics. 2018;20(10):E948-959. doi:
10.1001/amajethics.2018.948.